{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:41:06Z","timestamp":1777603266171,"version":"3.51.4"},"update-to":[{"DOI":"10.1002\/14651858.cd007325.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000}}],"reference-count":108,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007325.pub3","type":"journal-article","created":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T20:04:40Z","timestamp":1398974680000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion"],"prefix":"10.1002","volume":"2014","author":[{"given":"Tasanee","family":"Braithwaite","sequence":"first","affiliation":[{"name":"Moorfields Eye Hospital NHS Foundation Trust; 162 City Road London UK EC1V 2PD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afshan A","family":"Nanji","sequence":"additional","affiliation":[{"name":"Bascom Palmer Eye Institute; Miami Florida USA 33136"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Lindsley","sequence":"additional","affiliation":[{"name":"Johns Hopkins Bloomberg School of Public Health; Department of Epidemiology; 615 North Wolfe Street, W5010 Baltimore Maryland USA 21205"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul B","family":"Greenberg","sequence":"additional","affiliation":[{"name":"Warren Alpert Medical School of Brown University; Division of Ophthalmology; Providence Rhode Island USA 02908"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,5,1]]},"reference":[{"issue":"5","key":"10.1002\/14651858.CD007325.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.ophtha.2012.01.042","article-title":"Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study","volume":"119","author":"Boyer","year":"2012","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD007325.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ajo.2012.09.026","article-title":"Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study","volume":"155","author":"Brown","year":"2013","journal-title":"American Journal of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD007325.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.ophtha.2012.11.011","article-title":"Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography","volume":"120","author":"Bhisitkul","year":"2013","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD007325.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","article-title":"Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study","volume":"117","author":"Brown","year":"2010","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD007325.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.ophtha.2012.09.032","article-title":"Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion","volume":"120","author":"Campochiaro","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD007325.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.ophtha.2011.02.038","article-title":"Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study","volume":"118","author":"Campochiaro","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD007325.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ophtha.2011.12.005","article-title":"Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD007325.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jamaophthalmol.2013.114","article-title":"Reading speed improvements in retinal vein occlusion after ranibizumab treatment","volume":"131","author":"Suner","year":"2013","journal-title":"JAMA Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD007325.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/j.ophtha.2012.05.017","article-title":"Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion","volume":"119","author":"Varma","year":"2012","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD007325.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1016\/j.ophtha.2012.06.037","article-title":"Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results from a prospective, randomized study","volume":"119","author":"Epstein","year":"2012","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD007325.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.ophtha.2012.01.022","article-title":"Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study","volume":"119","author":"Epstein","year":"2012","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD007325.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/bjophthalmol-2012-301504","article-title":"VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study","volume":"97","author":"Holz","year":"2013","journal-title":"British Journal of Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD007325.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ophtha.2013.08.012","article-title":"Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the Phase 3 GALILEO Study","volume":"121","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD007325.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ajo.2010.03.028","article-title":"Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC Study","volume":"150","author":"Kinge","year":"2010","journal-title":"American Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD007325.pub3-BIB0015|cit15","unstructured":"Ciulla TA Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one-year study American Academy of Ophthalmology"},{"key":"10.1002\/14651858.CD007325.pub3-BIB0016|cit16","unstructured":"Csaky KG Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation American Academy of Ophthamology"},{"key":"10.1002\/14651858.CD007325.pub3-BIB0017|cit17","unstructured":"Patel SS Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes Investigative Ophthalmology and Visual Science 2007 ARVO E-abstract 311"},{"key":"10.1002\/14651858.CD007325.pub3-BIB0019|cit18","unstructured":"Wells JA Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion Investigative Ophthalmology and Visual Science 2006 ARVO E-abstract 4279"},{"key":"10.1002\/14651858.CD007325.pub3-BIB0020|cit19","unstructured":"Wells JA Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion American Academy of Ophthalmology"},{"key":"10.1002\/14651858.CD007325.pub3-BIB0018|cit20","unstructured":"Wells JA Wroblewski JJ Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes Investigative Ophthalmology and Visual Science 2007 ARVO E-abstract 1544"},{"issue":"4","key":"10.1002\/14651858.CD007325.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/archophthalmol.2009.14","article-title":"Pegaptanib sodium for macular edema secondary to central retinal vein occlusion","volume":"127","author":"Wroblewski","year":"2009","journal-title":"Archives of Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD007325.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00417-008-0917-1","article-title":"Prolongation of activity of single intravitreal bevacizumab by adjuvant topical aqueous depressant (Timolol-Dorzolamide)","volume":"247","author":"Byeon","year":"2009","journal-title":"Graefes Archive for Clinical and Experimental Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD007325.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/mt.2008.10","article-title":"Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator","volume":"16","author":"Campochiaro","year":"2008","journal-title":"Molecular Therapy"},{"key":"10.1002\/14651858.CD007325.pub3-BIB0024|cit24","doi-asserted-by":"crossref","unstructured":"Campochiaro PA Shah SM Hafiz G Quinlan E Zimmer-Gller I Nguyen QD Ranibizumab for macular edema due to retinal vein occlusions Investigative Ophthalmology and Visual Science 2007","DOI":"10.1038\/sj.mt.6300416"},{"issue":"5","key":"10.1002\/14651858.CD007325.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/IAE.0b013e3181f4420d","article-title":"Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion","volume":"31","author":"Ding","year":"2011","journal-title":"Retina (Philadelphia, Pa.)"},{"issue":"1","key":"10.1002\/14651858.CD007325.pub3-BIB0026|cit26","first-page":"89","article-title":"Intravitreal injection of bevacizumab alone or with triamcinolone acetonide for treatment of macular edema caused by central retinal vein occlusion","volume":"4","author":"Wang","year":"2011","journal-title":"International Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD007325.pub3-BIB0027|cit27","unstructured":"Habibabadi H Moradian S Piri N Esfahani M Aalami Z Lashay A Intravitreal bevacizumab vs combination of bevacizumab and triamcinolone vs sham treatment in central retinal vein occlusion American Academy of Ophthalmology"},{"key":"10.1002\/14651858.CD007325.pub3-BIB0028|cit28","unstructured":"Habibabadi HF Moradian S Piri N Esfahani MR Aalami Z Karkhaneh R Intravitreal bevacizumab vs combination of bevacizumab and triamcinolone vs sham treatment for central retinal vein occlusion American Academy of Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD007325.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/archopht.1996.01100130062010","article-title":"Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate","volume":"114","author":"Adamis","year":"1996","journal-title":"Archives of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD007325.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00417-012-2134-1","article-title":"A prospective, randomised, multicenter trial for surgical treatment of central retinal vein occlusion: results of the Radial Optic Neurotomy for Central Vein Occlusion (ROVO) study group","volume":"251","author":"Aggermann","year":"2013","journal-title":"Graefes Archive for Clinical and Experimental Ophthalmology"},{"issue":"23","key":"10.1002\/14651858.CD007325.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"10457","DOI":"10.1073\/pnas.92.23.10457","article-title":"Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins","volume":"92","author":"Aiello","year":"1995","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"8","key":"10.1002\/14651858.CD007325.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1097\/IAE.0b013e3181744153","article-title":"Radial optic neurotomy for central retinal vein occlusion: results of the Pan-American Collaborative Retina Study Group (PACORES)","volume":"28","author":"Arevalo","year":"2008","journal-title":"Retina"},{"issue":"12","key":"10.1002\/14651858.CD007325.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","article-title":"Pharmacokinetics of intravitreal ranibizumab (Lucentis)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD007325.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","article-title":"Pharmacokinetics of intravitreal bevacizumab\u00a0(Avastin)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD007325.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.ophtha.2007.06.047","article-title":"Visual acuity as an outcome measure in clinical trials of retinal disease","volume":"114","author":"Beck","year":"2007","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD007325.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.ophtha.2013.07.025","article-title":"Mortality in patients with central retinal vein occlusion","volume":"121","author":"Bertelsen","year":"2014","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD007325.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1001\/archopht.120.12.1644","article-title":"Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion","volume":"120","author":"Boyd","year":"2002","journal-title":"Archives of Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD007325.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.ophtha.2009.04.038","article-title":"Monitoring ocular drug therapy by analysis of aqueous samples","volume":"116","author":"Campochiaro","year":"2009","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD007325.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1016\/j.ophtha.2010.03.060","article-title":"Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two-year outcomes","volume":"117","author":"Campochiaro","year":"2010","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD007325.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ajo.2005.02.053","article-title":"Characterization of macular edema from various etiologies by optical coherence tomography","volume":"140","author":"Catier","year":"2005","journal-title":"American Journal of Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD007325.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.ophtha.2010.11.020","article-title":"SCORE Study report #11: incidences of neovascular events in eyes with retinal vein occlusion","volume":"118","author":"Chan","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD007325.pub3-BIB0042|cit42","first-page":"203-13; discuss","article-title":"Central Vein Occlusion Study: photographic protocol and early natural history","volume":"92","author":"Clarkson","year":"1994","journal-title":"Transactions of the American Ophthalmological Society"},{"issue":"10","key":"10.1002\/14651858.CD007325.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0161-6420(95)30849-4","article-title":"Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report","volume":"102","author":"CVOS Group","year":"1995","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD007325.pub3-BIB0044|cit44","first-page":"1275","article-title":"Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group","volume":"115","author":"CVOS Group","year":"1997","journal-title":"Archives of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD007325.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ajo.2008.10.024","article-title":"Pars plana vitrectomy, internal limiting membrane peeling, and panretinal endophotocoagulation for macular edema secondary to central retinal vein occlusion","volume":"147","author":"DeCroos","year":"2009","journal-title":"American Journal of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD007325.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000330279","article-title":"Effect of intravitreal anti-vascular endothelial growth factor treatment on the retinal gene expression in acute experimental central retinal vein occlusion","volume":"47","author":"Drechsler","year":"2012","journal-title":"Ophthalmic Research"},{"issue":"1","key":"10.1002\/14651858.CD007325.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nm811","article-title":"Cytokine traps: multi-component, high-affinity blockers of cytokine action","volume":"9","author":"Economides","year":"2003","journal-title":"Nature Medicine"},{"issue":"2","key":"10.1002\/14651858.CD007325.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.exer.2004.09.013","article-title":"Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown","volume":"80","author":"Edelman","year":"2005","journal-title":"Experimental Eye Research"},{"issue":"6","key":"10.1002\/14651858.CD007325.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1097\/01.iae.0000236461.31264.c6","article-title":"Venous occlusive disease: the latest in current management","volume":"26","author":"Everett","year":"2006","journal-title":"Retina"},{"key":"10.1002\/14651858.CD007325.pub3-BIB0050|cit50","unstructured":"Eyetech Inc Macugen - Pegatanib sodium injection www.macugen.com\/macugenUSPI.pdf 2008"},{"issue":"7","key":"10.1002\/14651858.CD007325.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"e68149","DOI":"10.1371\/journal.pone.0068149","article-title":"Differences in aqueous concentrations of cytokines in macular edema secondary to branch and central retinal vein occlusion.","volume":"8","author":"Feng","year":"2013","journal-title":"PLoS One"},{"issue":"8","key":"10.1002\/14651858.CD007325.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","article-title":"Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration","volume":"26","author":"Ferrara","year":"2006","journal-title":"Retina (Philadelphia, Pa.)"},{"issue":"3","key":"10.1002\/14651858.CD007325.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1167\/iovs.08-2510","article-title":"Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab","volume":"50","author":"Funk","year":"2009","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"10.1002\/14651858.CD007325.pub3-BIB0054|cit54","unstructured":"Genentech Inc Lucentis: Full prescribing information www.gene.com\/gene\/products\/information\/pdf\/lucentis-prescribing.pdf 2008"},{"key":"10.1002\/14651858.CD007325.pub3-BIB0055|cit55","unstructured":"Genentech Inc Avastin: Full prescribing information www.gene.com\/gene\/products\/information\/pdf\/avastin-prescribing.pdf 2009"},{"key":"10.1002\/14651858.CD007325.pub3-BIB0056|cit56","unstructured":"Genentech\/Roche Lucentis - Ranibizumab injection: Product Information Home www.gene.com\/gene\/products\/information\/tgr\/lucentis\/ 2009"},{"key":"10.1002\/14651858.CD007325.pub3-BIB0057|cit57","unstructured":"Genentech\/Roche Avastin: Product Information Home www.gene.com\/gene\/products\/information\/oncology\/avastin\/ 2009"},{"issue":"1","key":"10.1002\/14651858.CD007325.pub3-BIB0058|cit58","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007324.pub2","article-title":"Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion","author":"Gewaily","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD007325.pub3-BIB0059|cit59","first-page":"130","article-title":"How to identify randomized controlled trials in MEDLINE: ten years on","volume":"94","author":"Glanville","year":"2006","journal-title":"Journal of the Medical Library Association"},{"issue":"27","key":"10.1002\/14651858.CD007325.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD007325.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/IAE.0b013e3181d87e04","article-title":"Novel method for analyzing Snellen visual acuity measurements","volume":"30","author":"Gregori","year":"2010","journal-title":"Retina"},{"issue":"3-4","key":"10.1002\/14651858.CD007325.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1023\/A:1002130005227","article-title":"The pathogenesis and clinical presentation of macular edema in inflammatory diseases","volume":"97","author":"Guex-Crosier","year":"1999","journal-title":"Documenta Ophthalmologica"},{"issue":"8","key":"10.1002\/14651858.CD007325.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s00417-006-0501-5","article-title":"Treatment of central retinal vein occlusion by radial optic neurotomy in 107 cases","volume":"245","author":"Hasselbach","year":"2007","journal-title":"Graefes Archive for Clinical and Experimental Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD007325.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0161-6420(83)34530-9","article-title":"Classification of central retinal vein occlusion","volume":"90","author":"Hayreh","year":"1983","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD007325.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/BF00920022","article-title":"Differentiation of ischemic from non-ischemic central retinal vein occlusion during the early acute phase","volume":"228","author":"Hayreh","year":"1990","journal-title":"Graefes Archive for Clinical and Experimental Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD007325.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/BF00920049","article-title":"Argon laser panretinal photocoagulation in ischemic central retinal vein occlusion. A 10-year prospective study","volume":"228","author":"Hayreh","year":"1990","journal-title":"Graefes Archive for Clinical and Experimental Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD007325.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0002-9394(14)70001-7","article-title":"Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics","volume":"117","author":"Hayreh","year":"1994","journal-title":"American Journal of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD007325.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000068980","article-title":"Management of central retinal vein occlusion","volume":"217","author":"Hayreh","year":"2003","journal-title":"Ophthalmologica"},{"issue":"1","key":"10.1002\/14651858.CD007325.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ophtha.2010.04.019","article-title":"Natural history of visual outcome in central retinal vein occlusion","volume":"118","author":"Hayreh","year":"2011","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD007325.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archopht.1995.01100080071031","article-title":"Quantitative assessment of macular edema with optical coherence tomography","volume":"113","author":"Hee","year":"1995","journal-title":"Archives of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD007325.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ophtha.2011.12.005","article-title":"Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD007325.pub3-BIB0072|cit72","unstructured":"Higgins JPT Green S Chapter 8: Assessing risk of bias in included studies In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"issue":"3","key":"10.1002\/14651858.CD007325.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/107327480701400312","article-title":"Spectrum of activity and mechanism of action of VEGF\/PDGF inhibitors","volume":"14","author":"Homsi","year":"2007","journal-title":"Cancer Control"},{"issue":"4","key":"10.1002\/14651858.CD007325.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ajo.2008.05.036","article-title":"Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans","volume":"146","author":"Krohne","year":"2008","journal-title":"American Journal of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD007325.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1634\/theoncologist.12-4-443","article-title":"Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer","volume":"12","author":"Los","year":"2007","journal-title":"Oncologist"},{"issue":"4","key":"10.1002\/14651858.CD007325.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1345\/aph.1H316","article-title":"Bevacizumab for neovascular ocular diseases","volume":"41","author":"Lynch","year":"2007","journal-title":"Annals of Pharmacotherapy"},{"issue":"5","key":"10.1002\/14651858.CD007325.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.ophtha.2009.10.026","article-title":"The Central Retinal Vein Bypass Study: a trial of laser-induced chorioretinal venous anastomosis for central retinal vein occlusion","volume":"117","author":"McAllister","year":"2010","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD007325.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.ophtha.2010.01.060","article-title":"Natural history of central retinal vein occlusion: an evidence-based systematic review","volume":"117","author":"McIntosh","year":"2010","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD007325.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1755-3768.2010.02064.x","article-title":"Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections","volume":"89","author":"Meyer","year":"2011","journal-title":"Acta Ophthalmologica"},{"issue":"1","key":"10.1002\/14651858.CD007325.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2353\/ajpath.2007.061237","article-title":"Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury","volume":"171","author":"Nishijima","year":"2007","journal-title":"American Journal of Pathology"},{"issue":"3","key":"10.1002\/14651858.CD007325.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00006982-200603000-00008","article-title":"Radial optic neurotomy for central retinal vein occlusion: 117 consecutive cases","volume":"26","author":"Opremcak","year":"2006","journal-title":"Retina"},{"issue":"6","key":"10.1002\/14651858.CD007325.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","article-title":"Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion","volume":"117","author":"Haller","year":"2010","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD007325.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.ophtha.2011.05.014","article-title":"Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results","volume":"118","author":"Haller","year":"2011","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD007325.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1097\/IAE.0b013e3180603071","article-title":"Effect of oral pentoxifylline on cystoid macular edema associated with central retinal vein occlusion","volume":"27","author":"Park","year":"2007","journal-title":"Retina"},{"issue":"1","key":"10.1002\/14651858.CD007325.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/IAE.0b013e3181bced68","article-title":"Long-term effects of vitrectomy and internal limiting membrane peeling for macular edema secondary to central retinal vein occlusion and hemiretinal vein occlusion","volume":"30","author":"Park","year":"2010","journal-title":"Retina"},{"issue":"6","key":"10.1002\/14651858.CD007325.pub3-BIB0086|cit86","first-page":"638","article-title":"Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases","volume":"72","author":"Pe'er","year":"1995","journal-title":"Laboratory Investigation"},{"issue":"3","key":"10.1002\/14651858.CD007325.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0161-6420(98)93020-2","article-title":"Vascular endothelial growth factor upregulation in human central retinal vein occlusion","volume":"105","author":"Pe'er","year":"1998","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD007325.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.ophtha.2009.09.019","article-title":"Ultra wide-field angiographic characteristics of branch retinal and hemicentral retinal vein occlusion","volume":"117","author":"Prasad","year":"2010","journal-title":"Ophthalmology"},{"issue":"5-6","key":"10.1002\/14651858.CD007325.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000073587","article-title":"Retinal vein thrombosis: risk factors, pathogenesis and therapeutic approach","volume":"32","author":"Prisco","year":"2002","journal-title":"Pathophysiology of Haemostasis & Thrombosis"},{"issue":"6","key":"10.1002\/14651858.CD007325.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1177\/112067210901900625","article-title":"Pars plana vitrectomy with ILM peeling for macular edema secondary to retinal vein occlusion","volume":"19","author":"Raszewska-Steglinska","year":"2009","journal-title":"European Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD007325.pub3-BIB0091|cit91","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011"},{"issue":"2","key":"10.1002\/14651858.CD007325.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","article-title":"The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia","volume":"117","author":"Rogers","year":"2010","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD007325.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/archophthalmol.2009.234","article-title":"A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: The standard care vs corticosteroid for retinal vein occlusion (SCORE) study report 5","volume":"127","author":"Ip","year":"2009","journal-title":"Archives of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD007325.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/112067210301300505","article-title":"Central retinal vein occlusion risk profile: a case-control study","volume":"13","author":"Shahsuvaryan","year":"2003","journal-title":"European Journal of Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD007325.pub3-BIB0095|cit95","first-page":"1334","article-title":"Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis","volume":"37","author":"Shima","year":"1996","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"2","key":"10.1002\/14651858.CD007325.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ophtha.2012.07.080","article-title":"A longitudinal analysis of risk factors associated with central retinal vein occlusion","volume":"120","author":"Stem","year":"2013","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD007325.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/bjo.2007.134874","article-title":"Predicted biological activity of intravitreal VEGF Trap","volume":"92","author":"Stewart","year":"2008","journal-title":"British Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD007325.pub3-BIB0098|cit98","doi-asserted-by":"crossref","unstructured":"Stewart MW Grippon S Kirkpatrick P Aflibercept Nature Reviews. Drug Discovery 2012 269 70","DOI":"10.1038\/nrd3700"},{"issue":"8","key":"10.1002\/14651858.CD007325.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/IAE.0b013e3182278ab4","article-title":"A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections","volume":"31","author":"Reis","year":"2011","journal-title":"Retina (Philadelphia, Pa.)"},{"issue":"3-4","key":"10.1002\/14651858.CD007325.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1023\/A:1002136712070","article-title":"Cellular mechanisms of blood-retinal barrier dysfunction in macular edema","volume":"97","author":"Vinores","year":"1999","journal-title":"Documenta Ophthalmologica"},{"issue":"4","key":"10.1002\/14651858.CD007325.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"563","DOI":"10.5301\/ejo.5000089","article-title":"Clinical and electrophysiologic outcome in patients with neovascular glaucoma treated with and without bevacizumab","volume":"22","author":"Wittstrom","year":"2012","journal-title":"European Journal of Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD007325.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1167\/iovs.10-6097","article-title":"Predictors of short-term visual outcome after anti-VEGF therapy of macular edema due to central retinal vein occlusion","volume":"52","author":"Wolf-Schnurrbusch","year":"2011","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"5","key":"10.1002\/14651858.CD007325.pub3-BIB0103|cit103","first-page":"315","article-title":"Clinical case report: treatment of a central retinal vein occlusion with hyperbaric oxygen","volume":"34","author":"Wright","year":"2007","journal-title":"Undersea & Hyperbaric Medicine"},{"issue":"1","key":"10.1002\/14651858.CD007325.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00417-007-0660-z","article-title":"Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES)","volume":"246","author":"Wu","year":"2008","journal-title":"Graefes Archive for Clinical and Experimental Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD007325.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"5737","DOI":"10.1167\/iovs.10-6923","article-title":"Significant correlation between electroretinogram parameters and ocular vascular endothelial growth factor concentration in central retinal vein occlusion eyes","volume":"52","author":"Yasuda","year":"2011","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"5","key":"10.1002\/14651858.CD007325.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00417-004-1046-0","article-title":"Vitrectomy and radial optic neurotomy for central retinal vein occlusion: effects on visual acuity and macular anatomy","volume":"243","author":"Zambarakji","year":"2005","journal-title":"Graefes Archive for Clinical and Experimental Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD007325.pub3-BIB0107|cit107","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007325","article-title":"Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion","author":"Braithwaite","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD007325.pub3-BIB0108|cit108","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007325","article-title":"Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion","author":"Smith","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD007325.pub3\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T10:49:58Z","timestamp":1697885398000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD007325.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Eyes and Vision Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,5,1]]},"references-count":108,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007325.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,1]]}}}